ClinicalTrials.Veeva

Menu
S

Sunshine Coast University Private Hospital | Clinical Trials

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Sacituzumab
Etrasimod
ARV-471
PF-07850327
LM-108
BL0020
Nivolumab
HLX301

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 12 total trials

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: ARV-471
Drug: Fulvestrant

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinical expansion study will evaluate the safety, tole...

Enrolling
Locally Advanced or Metastatic Solid Tumors
Non-small Cell Lung Cancer
Drug: HLX301

This is the first in human study of BL0020, and the primary objective is to evaluate the safety and tolerability, and determine the maximum tolerated...

Enrolling
Advanced Solid Tumor
Drug: BL0020

This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokin...

Enrolling
Advanced Solid Tumor
Drug: An Anti-PD-1 Antibody
Drug: LM-108

The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or meta...

Active, not recruiting
Non-Small Cell Lung Cancer
Biological: Sacituzumab Govitecan-hziy (SG)
Drug: Docetaxel

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizu...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Sacituzumab Govitecan-hziy (SG)
Drug: Pembrolizumab

This is an open label, two-part, multicenter, multi-regional phase I trial to investigate the safety, tolerability, and PK of KGX101 monotherapy and...

Enrolling
Advanced or Metastatic Solid Tumors
Drug: KGX101 and Envafolimab
Drug: KGX101- Cohort 2

Trial sponsors

Pfizer logo
Gilead Sciences logo
A
Bristol-Myers Squibb (BMS) logo
H
K
L
S
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems